Johnson & Johnson delayed its vaccine rollout in the E.U. after the FDA and CDC paused use of the shot in the U.S. April 13 to review six reports of a rare but serious blood clotting side effect.
The EMA said the risk of blood clots outweighs the vaccine’s benefits. The agency also said the cases of blood clots linked to Johnson & Johnson’s shot are “very similar” to the blood clots associated with AstraZeneca’s vaccine, for which it made a similar recommendation.
The agency said E.U. member states can independently decide whether to continue using Johnson & Johnson’s shot, taking into account their COVID-19 case load and vaccine availability. The EMA also issued guidelines to help healthcare providers diagnose, treat and record any blood clots that could result from a COVID-19 vaccination.
More articles on pharmacy:
Half of US adults have received at least one COVID-19 vaccine dose
FDA limits emergency use of Eli Lilly COVID-19 antibody drug
Scant evidence links J&J vaccine, blood clots, drugmaker’s scientists say
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.